JAK/STAT-mediated regulation of PD-L1 expression in breast cancer: Molecular mechanisms and implications for immunotherapy
Abstract
models reveal that cytokines, hypoxia, metabolic remodeling, and extracellular vesicles sustain STAT-dependent PD-L1 programs that dampen cytotoxic immunity and promote resistance to therapy. The review further examines pharmacologic, genetic, and nanotechnology-based strategies that disrupt this signaling axis and enhance immune checkpoint efficacy, including combination regimens with chemotherapy, targeted therapy, and photodynamic approaches. Collectively, these findings position JAK/STAT-driven PD-L1 regulation as a unifying framework for understanding immune evasion and optimizing immunotherapy in breast cancer.
Fields of Study & Subjects
Cytokine Signaling Pathways and Interactions
Cancer Immunotherapy and Biomarkers
IL-33
ST2
and ILC Pathways
Publication details
- Journal / source
- iScience
- Publisher
- Elsevier BV
- Volume
- 29
- Issue
- 3
- Pages
- 114826–114826
- Publication date
- 30 January 2026
- Language
- EN